A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, maximum tolerated dose and
pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.